Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11505620 Methods of detecting plasma kallikrein

Patent 11505620 was granted and assigned to Takeda Pharmaceutical Company on November, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Takeda Pharmaceutical Company

Current Assignee

Takeda Pharmaceutical Company

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11505620

Date of Patent

November 22, 2022

Patent Application Number

16411242

Date Filed

May 14, 2019

Patent Citations

‌

US Patent 11046785 Compositions and methods for treatment of diabetic macular edema

‌

US Patent 10336832 Methods of inhibiting plasma kallikrein in edema patient

‌

US Patent 10370453 Plasma kallikrein binding proteins

‌

US Patent 10428158 Compositions and methods for treatment of diabetic macular edema

‌

US Patent 11084884 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Patent Citations Received

‌

US Patent 12084515 Compositions and methods for treatment of diabetic macular edema

Patent Primary Examiner

CPC Code

Plasma kallikrein binding proteins and methods of using such proteins are described.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11505620 Methods of detecting plasma kallikrein

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API